目的：观察七味止嗝方联合CF 化疗方案治疗中晚期气虚痰瘀型食管鳞癌的临床疗效及不良反应的影响。方法：选取100 例中晚期食管鳞癌患者，按掷币法分为对照组及观察组各50 例，对照组采用CF 化疗方案，观察组在对照组化疗基础上加用七味止嗝方治疗，2 组均以21 d 为1 个周期，共治疗2 个周期。比较2 组免疫功能指标及不良反应程度、肿瘤患者生活质量评分（QOL） 变化，比较2 组疾病控制率。结果：治疗后，2 组CD4+及CD4+/CD8+均较治疗前降低，观察组CD4+及CD4+/CD8+高于对照组，差异均有统计学意义（P＜0.05）。治疗后，观察组骨髓抑制［白细胞计数（WBC）、血小板（BPC）］、恶心呕吐及腹泻等不良反应程度低于对照组，差异均有统计学意义（P＜0.05）。治疗后，2 组QOL 中食欲情况、精神情况、疼痛程度、不良反应对生活的影响、对治疗的态度评分均较治疗前降低，对照组上述5 项评分均低于观察组，差异均有统计学意义（P＜0.05）。对照组疾病控制率为56.00%，观察组疾病控制率为68.00%，2 组比较，差异有统计学意义（P＜0.05）。结论：七味止嗝方联合CF化疗方案治疗中晚期食管鳞癌疗效显著，可减轻化疗不良反应，改善免疫功能，提高生活质量。
Abstract： Objective： To observe the clinical effect of Qiwei Zhige prescription combined with CF chemotherapy for advanced esophageal squamous cell carcinoma of qi deficiency with phlegm stasis type and its effect on adverse reactions. Methods：A total of 100 cases of patients with advanced esophageal squamous cell carcinoma were selected and divided into the observation group and the control group by coin- tossing method，with 50 cases in each group. The control group was given CF chemotherapy scheme，and the observation group was additionally given modified Qiwei Zhige prescription based on the treatment of the control group. Both groups were treated for two cycles， with 21 days being a cycle. Changes in indexes of immune function， degree of adverse reactions， scores of quality of life(QOL) in cancer patients， and disease control rates were compared between the two groups. Results：After treatment，CD4 + and CD4 +/CD8 + in the two groups were decreased when compared with those before treatment，and CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group，differences being significant(P＜0.05). After treatment，myelosuppression ［white blood cell count(WBC)，platelet(BPC)] as well as degree of adverse reactions including nausea，vomiting and diarrhea in the observation group were lower than those in the control group，differences being significant(P＜0.05). After treatment，appetite，mental status，pain degree，effects of adverse reactions on life，attitude to treatment in QOL in the two groups were decreased when compared with those before treatment，and the above five scores in the control group were lower than those in the observation group， differences being significant(P＜0.05). The disease control rate was 56.00% in the control group and 68.00% in the observation group，the difference being significant(P＜0.05). Conclusion：Qiwei Zhige prescription combined with CF chemotherapy has a significant curative effect on patients with advanced esophageal squamous cell carcinoma， which can relieve adverse reactions of chemotherapy，and improve immune function and quality of life.